{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 14 of 128', 'Table of contents', 'Clinical trial protocol statements', '2', 'Protocol amendment summary of changes table', '3', 'Table of contents', '14', 'List of abbreviations', '20', '1 Protocol synopsis', '22', '2 Trial identification', '27', '3 Schematic of trial design', '27', '4', 'Schedule of trial procedures', '28', '5 Introduction and trial rationale', '33', '5.1 Chronic hand eczema', '33', '5.2 Experience with investigational medicinal product', '34', '5.3 Trial rationale', '36', '5.4 Justification for dose', '36', '5.5 Ethical considerations', '37', '5.6 Benefit/risk assessment', '38', '6 Trial objectives and endpoints', '39', '7 Trial design', '41', '7.1 Overall trial design', '41', '7.2 Number of subjects needed', '42', '7.3', 'End of trial definition', '42', '7.4 Software', '43', '8 Trial population', '44', '8.1', 'Subject eligibility', '44', '8.2', 'Inclusion criteria', '44', '8.3 Exclusion criteria', '45', '8.4 Screening and screening failures', '48', '9 Treatments', '50', '9.1 Trial product description', '50', '9.2 Administration of IMP', '50']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 15 of 128', '9.3 Treatment assignment', '51', '9.3.1 Blinding', '51', '9.3.2', 'Emergency unblinding of individual subject treatment', '51', '9.4 Background treatment (emollients)', '52', '9.5 Rescue treatment', '52', '9.6 Concomitant medication and concurrent procedures', '52', '9.7 Prohibited medication and procedures', '54', '9.8 Treatment logistics and accountability', '56', '9.8.1 Labelling and packaging of trial products', '56', '9.8.2', 'Storage of trial products', '56', '9.8.3', 'Drug accountability', '57', '9.8.4', 'Treatment compliance', '57', '9.8.5', 'Trial product destruction', '58', '9.9 Provision for subject care following trial completion', '58', '9.10 Reporting product complaints', '58', '10 Discontinuation and withdrawal', '59', '10.1 General principles', '59', '10.2 IMP discontinuation rules', '59', '10.2.1 Reasons for discontinuation of IMP', '59', '10.3 Early termination assessments', '60', '10.4 Lost to follow-up', '61', '11 Trial assessments and procedures', '62', '11.1 Overview', '62', '11.2 Assessments performed only at screening/baseline', '63', '11.2.1 Demographics', '63', '11.2.2 Fitzpatrick skin type', '64', '11.2.3', 'Medical history', '64', '11.2.4 Classification of chronic hand eczema', '67', '11.2.5 Height and weight', '67', '11.2.6 Determination of treatment area', '67', '11.3 Efficacy assessments', '68', \"11.3.1 Investigator's Global Assessment (IGA)\", '68', '11.3.2 Hand Eczema Severity Index (HECSI)', '69', '11.4 Safety assessments', '71']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 16 of 128', '11.4.1 Vital signs', '71', '11.4.2 Physical examination', '71', '11.4.3', 'ECG', '72', '11.4.4 Laboratory testing', '73', '11.4.5 Subject assessment of local tolerability', '75', '11.5 Pharmacokinetic assessments', '76', '11.5.1 Blood sampling for analysis of systemic concentration of delgocitinib', '76', '11.6 Pharmacodynamics and pharmacogenomics', '76', '11.6.1 Overview', '76', '11.6.2', 'Skin swabs', '77', '11.6.3', 'Skin biopsies and photographs (all sites, but optional)', '78', '11.6.4 Filaggrin mutations', '80', '11.6.5 Non-invasive measurements of skin barrier function (selected trial sites)', '80', '11.7 Other assessments', '81', '11.7.1 Patient-reported outcomes (PROs)', '81', '11.7.1.1 Chronic Hand Eczema Symptom Diary (HESD)', '82', '11.7.1.2', 'Chronic Hand Eczema Impact Scale (HEIS)', '82', '11.7.1.3', \"Patient's Global Assessment (PaGA)\", '82', '11.7.1.4', 'Patient Global Impression of Change (PGI-C)', '82', '11.7.1.5', 'Dermatology Life Quality Index (DLQI)', '83', '11.7.1.6', 'EuroQoL 5-dimension health questionnaire 5-level (EQ-5D-', '5L)', '83', '11.7.1.7 Quality of Life in Hand Eczema Questionnaire (QOLHEQ) 83', '11.7.1.8 Work Limitation Questionnaire (WLQ)', '83', '11.8 Estimate of total blood volume collected', '84', '11.9 End of trial', '84', '11.10Storage of biological samples', '84', '12 Scientific rationale for trial design and appropriateness of assessments', '86', '13 Adverse events', '87', '13.1 Definition and classification of adverse events', '87', '13.2 Collection of adverse event reports', '87', '13.3 Reporting of adverse events', '87', '13.4 Reporting of serious adverse events', '88', '13.4.1 Investigator reporting responsibilities', '88', '13.4.2 LEO reporting responsibilities', '89', '13.5 Other events that require expedited reporting', '90']\n\n###\n\n", "completion": "END"}